celecoxib/ciprofloxacin (PrimeC)

Indications

• treatment of patients with amyotrophic lateral sclerosis (ALS)
  • slower functional decline
  • reduced risk of ALS-related complications
  • increased probability of overall survival

Adverse effects

• safety profile comparable to placebo over 18 months

More general terms

• neurologic agent
• pharmacologic combination

Components

• celecoxib (Celebrex)
• ciprofloxacin (Cipro, Ciloxan)